Recent Articles
The Eye of a Survivor
While cure remains a goal, unique issues arise when treating professional and amateur athletes for hematologic conditions.
Athletic competition on an elite level depends on...
August 2021 Volume 7 Issue 10
This issue explores hematologic conditions in athletes, blue top tube shortages, and more.
Investigating the Combination of Ivosidenib Plus Venetoclax and Azacitidine in IDH-Mutated Myeloid Malignancies
In a small study of patients with IDH1-mutated myeloid malignancies, treatment with ivosidenib plus venetoclax, with or without azacitidine, had an acceptable safety profile and led to high...
Evaluating Two New Options for Hereditary Hemorrhagic Telangiectasia
At EHA2021 Virtual, researchers shared safety and efficacy findings of two agents for the treatment of the rare disease hereditary hemorrhagic telangiectasia (HHT): pazopanib...
Ibrutinib Plus Rituximab Shows Efficacy in Indolent Mantle Cell Lymphoma
In the GELTAMO ICML-2015 study, treatment with frontline ibrutinib in combination with rituximab demonstrated high rates of efficacy in patients with indolent mantle cell...
Current Issue
August 2021 Volume 7 Issue 10
This issue explores hematologic conditions in athletes, blue top tube shortages, and more.